Abstract

IntroductionTriple-negative (TN) breast cancer represents one third of pregnancy-associated breast cancers (PABC). The aims of the current study were to describe oncological and obstetrical outcomes of patients with TN-PABC and to compare their prognosis with TN-non-PABC patients using a propensity score. Materials and methodsBetween January 2005 and December 2020, data of patients with histologically proven TN-PABC were collected and compared with data of TN-non-PABC patients under the age of 46 years diagnosed during the same period using a propensity score (PS). ResultsAfter PS matching (tumor size and lymph node involvement),there were 59 patients in each group. The median follow-up was 14 months (IQR 4.8–40.1) for the TN-PABC group and 60 months (IQR 30.7–101.4) for the TN-non-PABC group. Eight recurrences occurred in the TN-PABC group and 10 in the TN-non-PABC group (adjusted OR (AOR) = 0.60 (0.21–1.60), HR (Cox adjusted model- AHR) = 1.25 (0.53–2.94)). Two patients died in the TN-PABC group, and six in the TN-non-PABC group with an AOR = 0.23 (0.03–1.01) and an AHR = 0.58 (0.12–2.69). All the patients diagnosed during the second (n = 17) and third trimesters (n = 28) continued their pregnancies, with a median term at delivery of 38 WG (IQR 36–39). All patients gave birth to healthy newborns. ConclusionAlthough the TN subtype is associated with poor prognosis in pregnant patients due to advanced stage at diagnosis and high lymph node involvement, our PS-matched case-control study showed that pregnancy per se does not worsen the prognosis in terms of recurrence-free and overall survival.

Highlights

  • Triple-negative (TN) breast cancer represents one third of pregnancy-associated breast cancers (PABC)

  • The triple-negative pregnancy associated breast cancer (TN-PABC) were diagnosed at more advanced stages than the TN-non-PABCs, no differences were found in recurrence-free survival (RFS) and overall survival (OS) between the two groups after PS matching (PSM) analysis, suggesting that both populations should be managed in the same way

  • After adjusting for age, stage, grade, hazard ratios (HRs) status, human epidermal growth factor receptor 2 (HER2) status, histology, type of chemotherapy, use of trastuzumab, radiotherapy, and hormone therapy, both DFS and OS were similar in both groups of patients [17]

Read more

Summary

Introduction

Triple-negative (TN) breast cancer represents one third of pregnancy-associated breast cancers (PABC). Materials and methods: Between January 2005 and December 2020, data of patients with histologically proven TN-PABC were collected and compared with data of TN-non-PABC patients under the age of 46 years diagnosed during the same period using a propensity score (PS). Eight recurrences occurred in the TN-PABC group and 10 in the TN-non-PABC group (adjusted OR (AOR) 1⁄4 0.60 (0.21e1.60), HR (Cox adjusted model- AHR) 1⁄4 1.25 (0.53 e2.94)). Two patients died in the TN-PABC group, and six in the TN-non-PABC group with an AOR 1⁄4 0.23 (0.03e1.01) and an AHR 1⁄4 0.58 (0.12e2.69). Conclusion: the TN subtype is associated with poor prognosis in pregnant patients due to advanced stage at diagnosis and high lymph node involvement, our PS-matched case-control study showed that pregnancy per se does not worsen the prognosis in terms of recurrence-free and overall survival. This rate is on the increase as more women delay childbearing [4,6,8e12]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call